Elixinol Wellness Limited (EXL) Fair Value & Analysis
Healthcare · AU · Market cap A$3.3M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0800 to A$0.0080 (−90.0%) since Jun 24, 2026. Share price −25.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0060 – A$0.0200 · fair‑value band A$0.0068 – A$0.0086 · the A$0.0060 price screens below the A$0.0080 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Elixinol Wellness Limited (EXL) currently trades at A$0.0060, while our model-based Fair Value estimate is A$0.0080 — implying the stock looks roughly 34.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Elixinol Wellness Limited generated revenue of A$15.5M at a net margin of -35.5%. Revenue declined 4.3% year over year. It earns a return on equity of -62.9%. Net debt stands at A$2.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Elixinol Wellness Limited reported revenue of A$15.5M in FY2025 versus A$9.3M in FY2021, a compound +13.5%/yr. Reported net income was −A$5.5M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Elixinol Wellness Limited (EXL) undervalued?
What is the fair value of EXL?
What is the quality score of EXL?
What is the revenue of Elixinol Wellness Limited (EXL)?
What is the net profit margin of EXL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.